女性の健康治療薬市場規模、シェア、成長分析：年齢別、薬剤別、流通チャネル別、用途別、地域別 - 産業予測 2025～2032年

女性の健康治療薬市場規模は2023年に137億米ドルと評価され、2024年の144億5,000万米ドルから2032年には221億8,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは5.5％で成長する見通しです。

世界の女性の健康治療薬市場は消費者の嗜好の変化を目の当たりにしており、健康的なスナック、特にフルーツスナックへの需要が高まっています。この分野は、フルーツスナックが便利で健康的な代替品であるという認識により、回復力と着実な成長を示しています。消費者の健康志向の高まりに伴い、低カロリーで人工添加物を使用せず、本物の果実を原材料とするスナック菓子を好む傾向が顕著になっています。このような健康志向の動向は、市場にさらなる影響を与えると予想されます。これを受けて、フルーツスナック分野の企業は、オーガニック、非遺伝子組み換え、クリーンラベルのオプションを発売することで製品イノベーションに投資しており、また、より多くの消費者を惹きつけるために新しいフレーバーやパッケージングソリューションも模索しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

女性の健康治療薬市場規模：年齢別& CAGR（2025-2032）

• 市場概要
• 50歳以上
• その他

女性の健康治療薬市場規模：薬剤別& CAGR（2025-2032）

• 市場概要
• アクトンエル
• YAZヤスミンヤスミネル
• フォルテオ
• ミナストリン24 Fe
• ミレーナ
• ヌーバリング
• オルソトリサイ LO
• プレマリン
• プロリア
• レクラスト/アクラスタ
• ゼヴァ
• ゾメタ
• その他

女性の健康治療薬市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

女性の健康治療薬市場規模：用途別& CAGR（2025-2032）

• 市場概要
• ホルモン性不妊症
• 避妊薬
• 閉経後骨粗鬆症
• 子宮内膜症と子宮筋腫
• 閉経
• 多嚢胞性卵巣症候群（PCOS）

女性の健康治療薬市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Hologic, Inc.（United States）
• Pfizer Inc.（United States）
• AbbVie Inc.（United States）
• Bayer AG（Germany）
• Johnson & Johnson（United States）
• Eli Lilly and Company（United States）
• Sanofi S.A.（France）
• Gedeon Richter Plc.（Hungary）
• Sumitomo Pharma Co., Ltd.（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Novartis AG（Switzerland）
• Merck & Co., Inc.（United States）
• AstraZeneca plc（United Kingdom）
• Organon & Co.（United States）
• Amgen Inc.（United States）
• F. Hoffmann-La Roche AG（Switzerland）
• Mithra Pharmaceuticals（Belgium）
• Aspira Women's Health Inc.（United States）
• Evofem Biosciences, Inc.（United States）

結論と提言

Women's Health Therapeutics Market size was valued at USD 13.7 billion in 2023 and is poised to grow from USD 14.45 billion in 2024 to USD 22.18 billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).

The global women's health therapeutics market is witnessing a shift in consumer preferences, with an increasing demand for healthier snack options, particularly fruit snacks. This segment has shown resilience and steady growth, driven by the perception of fruit snacks as convenient and healthier alternatives. As consumers become more health-conscious, there is a notable preference for snacks that are low in calories, free from artificial additives, and composed of real fruit ingredients. This health-focused trend is expected to influence the market further. In response, companies in the fruit snacks sector are investing in product innovation by launching organic, non-GMO, and clean-label options, while also exploring new flavors and packaging solutions to attract a wider audience.

Top-down and bottom-up approaches were used to estimate and validate the size of the Women's Health Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Women's Health Therapeutics Market Segments Analysis

Global Women's Health Therapeutics Market is segmented by Age, Drug, Distribution Channel, Application and region. Based on Age, the market is segmented into 50 Years & Above and Others. Based on Drug, the market is segmented into ACTONEL, YAZ, Yasmin, Yasminelle, FORTEO, Minastrin 24 Fe, Mirena, NuvaRing, ORTHO TRI-CY LO, Premarin, Prolia, Reclast/Aclasta, XGEVA, Zometa and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Application, the market is segmented into Hormonal Infertility,contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause and Polycystic Ovary Syndrome (PCOS). Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Women's Health Therapeutics Market

The growing awareness and advocacy surrounding women's health issues have significantly boosted the demand for advanced therapeutic solutions tailored to conditions like menopause, reproductive disorders, and hormonal imbalances. This heightened interest is driving the market for women's health therapeutics, as consumers seek more effective treatments. Moreover, technological advancements in healthcare, such as precision medicine and the development of innovative drug formulations, are further accelerating therapeutic innovation in this sector. These factors collectively contribute to a dynamic market environment that prioritizes improved health outcomes for women, ensuring a continuous evolution in the therapeutic landscape designed specifically for female patients.

Restraints in the Women's Health Therapeutics Market

A significant constraint in the Women's Health Therapeutics market is the intricate regulatory landscape, characterized by rigorous approval processes that can delay product launches. This complexity often arises from concerns about potential side effects and safety risks linked to various therapeutic options, which can affect both regulatory evaluations and patient acceptance. Furthermore, persistent gender disparities in clinical research and access to healthcare services hinder the development of inclusive and effective therapeutic solutions for women's health. These factors together create substantial barriers, impacting the overall progress of innovation and availability in this essential market sector.

Market Trends of the Women's Health Therapeutics Market

The Women's Health Therapeutics market is experiencing a notable trend towards personalized medicine, emphasizing customized therapeutic approaches that consider genetic, hormonal, and lifestyle factors unique to women. This shift is fostering innovation in contraception, particularly with advancements in long-acting reversible contraceptives (LARCs) and the emergence of non-hormonal options. Furthermore, there is an increasing focus on developing novel therapies to address specific health issues such as endometriosis and polycystic ovary syndrome (PCOS). This holistic and tailored approach not only enhances treatment effectiveness but also empowers women to take charge of their health, marking a pivotal shift in the market landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Women's Health Therapeutics Market Size by Age & CAGR (2025-2032)

• Market Overview
• 50 Years & Above
• Others

Global Women's Health Therapeutics Market Size by Drug & CAGR (2025-2032)

• Market Overview
• ACTONEL
• YAZ, Yasmin, Yasminelle
• FORTEO
• Minastrin 24 Fe
• Mirena
• NuvaRing
• ORTHO TRI-CY LO
• Premarin
• Prolia
• Reclast/Aclasta
• XGEVA
• Zometa
• Others

Global Women's Health Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Women's Health Therapeutics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Hormonal Infertility
• Contraceptives
• Postmenopausal Osteoporosis
• Endometriosis & Uterine Fibroids
• Menopause
• Polycystic Ovary Syndrome (PCOS)

Global Women's Health Therapeutics Market Size & CAGR (2025-2032)

• North America (Age, Drug, Distribution Channel, Application)
  • US
  • Canada
• Europe (Age, Drug, Distribution Channel, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Age, Drug, Distribution Channel, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Age, Drug, Distribution Channel, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Age, Drug, Distribution Channel, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Hologic, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gedeon Richter Plc. (Hungary)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Pharma Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organon & Co. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mithra Pharmaceuticals (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aspira Women's Health Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evofem Biosciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations